Cutaneous Squamous Cell Carcinoma - Updates in Immunotherapy presented by Dr. Butler MD

Watch a live recording of our recent webinar with Dr. Marcus Butler, MD on the "Evolving Landscape of Cutaneous Squamous Cell Carcinoma Treatment: Updates on Immunotherapy Treatment"
Cutaneous Squamous Cell Carcinoma (cSCC) is the second most common form of skin cancer in Canada, with an estimated 16,000+ patients nationally. It is forecasted that anywhere from 200-700 of these patients have locally advanced or metastatic cSCC.
This livestreaming program targets surgeons from a number of specialties that are involved in the treatment of cSCC patients, to advise on a new, recently approved curative treatment. Cemiplimab is a fully-human monoclonal antibody that is the first and only biologic immunotherapy treatment specifically approved and available for adult patients with metastatic or locally advanced cSCC.
You Are Not Alone - cSCC patient support
www.melanomanetwork.ca/csccin...
Download a copy of our cSCC patient guide - Helping You Understand cutaneous Squamous Cell Carcinoma (cSCC) A Patient Guide
www.melanomanetwork.ca/csccin...
cSCC Treatment information
www.melanomanetwork.ca/csccin...
About Dr. Marcus Butler
Dr. Marcus Butler, MD
Medical Oncologist, Princess Margaret Cancer Centre,
University Health Networ
Melanoma Network of Canada
www.melanomanetwork.ca/
1.877.560.8035
[e-mail]
Facebook
/ melanomanetwork
Twitter
/ melanomanetwork
Instagram
/ melanomanetwork

[@jeffsmithist]

Note that 85yo was going to be assisted in dying by the medical Dr. Later received care and was doing well. Don’t let the Dr help you DIE